| 30 Dec 2011 |
Share dealing by a Person Discharging Managerial Responsibility |
| 15 Dec 2011 |
Shire plc Board and Committee Changes |
| 14 Dec 2011 |
Director/PDMR Shareholding |
| 12 Dec 2011 |
Director/PDMR Shareholding |
| 08 Dec 2011 |
Shire Reports Positive Phase II Results for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) |
| 02 Dec 2011 |
ProAmatine® Update: Path Forward Agreed |
| 01 Dec 2011 |
ADDERALL® (mixed salts of a single-entity amphetamine product) Supply Clarification |
| 01 Dec 2011 |
Director/PDMR Shareholding |
| 01 Dec 2011 |
Total Voting Rights |
| 24 Nov 2011 |
Block listing six monthly return |
| 22 Nov 2011 |
Shire Announces Regulatory Filings in US and EU for New Manufacturing Facility |
| 21 Nov 2011 |
Director/PDMR Shareholding |
| 18 Nov 2011 |
BRAVE Awards Recipients Announced |
| 18 Nov 2011 |
Shire Announces Strategic Partnership for ADHD Medicines in Japan with Shionogi & Co., Ltd. |
| 07 Nov 2011 |
Director/PDMR Shareholding |
| 02 Nov 2011 |
PDMR Share Transactions |
| 01 Nov 2011 |
Total Voting Rights |
| 01 Nov 2011 |
Director Declaration |
| 28 Oct 2011 |
Continued strong product sales performance in Q3: On track to deliver significant 2011 earnings growth |
| 21 Oct 2011 |
EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD |
| 20 Oct 2011 |
Bloomberg interview - Shire To Expand in Regenerative Medicine, CEO Says |
| 13 Oct 2011 |
Shire Canada grants SickKids $200,000 to support paediatric research and ADHD |
| 13 Oct 2011 |
Third quarter 2011 results date notification – October 28, 2011 |
| 03 Oct 2011 |
Total Voting Rights |
| 30 Sep 2011 |
Director/PDMR Shareholding |
| 26 Sep 2011 |
Director/PDMR Shareholding |
| 22 Sep 2011 |
Shire Provides Update on ProAmatine® (midodrine HCl) |
| 01 Sep 2011 |
Elections for Interim Dividend in Respect of the Six Months to June 30, 2011 |
| 01 Sep 2011 |
Total Voting Rights |
| 25 Aug 2011 |
FDA Approves Shire’s FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) |
| 24 Aug 2011 |
Top-Line Results from Pivotal Trial of Dermagraft® for Venous Leg Ulcers |
| 12 Aug 2011 |
Purchase of Shares by Employee Benefit Trust |
| 11 Aug 2011 |
Half Yearly Report |
| 03 Aug 2011 |
Director/PDMR Shareholding |
| 02 Aug 2011 |
Director/PDMR Shareholding |
| 01 Aug 2011 |
Director/PDMR Shareholding |
| 01 Aug 2011 |
Total Voting Rights |
| 29 Jul 2011 |
Notification of major interests in shares (26KB PDF) |
| 28 Jul 2011 |
Shire's quarterly revenues grow by 25% to $1 billion for the first time |
| 27 Jul 2011 |
Board Changes |
| 18 Jul 2011 |
Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis |
| 15 Jul 2011 |
Second quarter 2011 results date notification – July 28, 2011 |
| 08 Jul 2011 |
Shire named “Business of the Year” at 2011 First Women Awards |
| 07 Jul 2011 |
Shire files lawsuits against Watson and Roxane for infringement of VYVANSE® (lisdexamfetamine dimesylate) patents |
| 01 Jul 2011 |
Shire files lawsuits against Sandoz and Amneal for infringement of VYVANSE® |
| 01 Jul 2011 |
Total Voting Rights |
| 28 Jun 2011 |
Shire completes acquisition of Advanced BioHealing, Inc. |
| 27 Jun 2011 |
Shire named "Company of the Year" at Mediscience Awards for second consecutive year |
| 24 Jun 2011 |
European Authorities Approve New Manufacturing Facility for Shire’s REPLAGAL® (agalsidase alfa) |
| 24 Jun 2011 |
Purchase of Shares by Employee Benefit Trust |
| 23 Jun 2011 |
FDA Advisory Committee Strongly Recommends Approval and Self-Administration of FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema |
| 21 Jun 2011 |
Shire Launches BRAVE Awards to Recognize Caregivers |
| 21 Jun 2011 |
Director/PDMR Shareholding |
| 21 Jun 2011 |
Shire Launches First BRAVE Awards to Recognise Carers |
| 20 Jun 2011 |
Maroon 5 Lead Singer Adam Levine Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults With "Own It" |
| 17 Jun 2011 |
Director/PDMR Shareholding |
| 14 Jun 2011 |
Shire Announces Judges Panel for New Scholarship Program for Students Diagnosed with ADHD |
| 07 Jun 2011 |
Health Canada grants MEZAVANT® new expanded indication for maintenance of remission of Ulcerative Colitis |
| 01 Jun 2011 |
Total Voting Rights |
| 28 May 2011 |
First Results of European Survey Show Significant Impact Of ADHD At School And Home, Yet Parents Wait Over Two Years for An ADHD Diagnosis |
| 25 May 2011 |
Calling All Students Diagnosed with ADHD – There’s a Scholarship for You! |
| 25 May 2011 |
Shire Receives VYVANSE® Paragraph IV Notice Letters |
| 24 May 2011 |
Block listing six monthly return |
| 19 May 2011 |
Shire Receives VYVANSE® Paragraph IV Notice Letter |
| 17 May 2011 |
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc., including US marketed DERMAGRAFT® |
| 12 May 2011 |
Bloomberg interview with Angus Russell, CEO |
| 09 May 2011 |
Director/PDMR Shareholding |
| 06 May 2011 |
Purchase of Shares by Employee Benefit Trust |
| 04 May 2011 |
Director Declaration |
| 03 May 2011 |
Total Voting Rights |
| 28 Apr 2011 |
Shire delivers a strong first quarter performance |
| 28 Apr 2011 |
Shire Reports Positive Results from Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as Adjunctive Treatment in Predominant Negative Symptom Schizophrenia |
| 26 Apr 2011 |
Results of the Annual General Meeting (20KB PDF) |
| 21 Apr 2011 |
First quarter 2011 results date notification – April 28, 2011 |
| 19 Apr 2011 |
Notification of major interests in shares |
| 06 Apr 2011 |
Shire files lawsuit against Watson Pharmaceuticals, Inc. for infringement of ADDERALL XR® patents and for breach of contract. |
| 01 Apr 2011 |
Director/PDMR Shareholding |
| 01 Apr 2011 |
Total Voting Rights |
| 01 Apr 2011 |
Annual Information Update |
| 29 Mar 2011 |
Notification of major interests in shares (45KB PDF) |
| 24 Mar 2011 |
2010 Annual Report – DTR 6.3.5 Disclosure |
| 21 Mar 2011 |
FDA Assigns PDUFA Date for Shire’s FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema |
| 21 Mar 2011 |
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) |
| 03 Mar 2011 |
European Commission Approves Self-Administration Label for FIRAZYR® (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks |
| 02 Mar 2011 |
Correction: Director/PDMR Shareholding |
| 01 Mar 2011 |
Director/PDMR Shareholding |
| 01 Mar 2011 |
Total Voting Rights |
| 01 Mar 2011 |
Elections for Interim Dividend in Respect of the Six Months to December 31, 2010 |
| 28 Feb 2011 |
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents |
| 28 Feb 2011 |
Shire Supports World Rare Disease Day 2011 |
| 28 Feb 2011 |
Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema |
| 24 Feb 2011 |
Shire Receives new Paragraph IV Notice Letter From Watson for ADDERALL XR® |
| 10 Feb 2011 |
Outstanding 2010 results: Non GAAP EPS up 21% to $4.23. Good earnings growth expected in 2011. |
| 08 Feb 2011 |
Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments |
| 02 Feb 2011 |
Santé Canada approuve Vyvanse® pour le traitement du TDAH chez les adolescents et les adultes |
| 02 Feb 2011 |
Health Canada Approves Vyvanse® for the Treatment of ADHD in Adolescents and Adults |
| 01 Feb 2011 |
Total voting Rights |
| 31 Jan 2011 |
Full Year 2010 results date notification – February 10, 2011 |
| 27 Jan 2011 |
Shire Appoints New Head of European Government Relations and Public Policy |
| 24 Jan 2011 |
Shire Recognized by ISPE Facility of the Year Awards Program |
| 10 Jan 2011 |
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model |
| 04 Jan 2011 |
Total Voting Rights |
